| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3729 |
| Trial ID | NCT06220201 |
| Disease | Multiple Sclerosis |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CC-97540|BMS-986353 |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | A Phase 1, Multicenter, Single-arm, Dose-escalation Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, Evaluating Safety and Tolerability in Participants With Relapsing Forms of Multiple Sclerosis (RMS) or Progressive Forms of Multiple Sclerosis (PMS) |
| Year | 2024 |
| Country | Belgium|France|Germany|Italy|Spain|United Kingdom|United States |
| Company sponsor | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company |
| Other ID(s) | CA061-1006 |
| Cohort 1 | |||||||||
|
|||||||||